Richard Alan Engh
Philip Ben Rainsford,
Fredrik G. Rylandsholm,
Martin Jakubec,
Mitchell Silk,
Eric Juskewitz,
Johanna Ulrica Ericson
et al.:
Label-free measurement of antimicrobial peptide interactions with lipid vesicles and nanodiscs using microscale thermophoresis
Wenche Stensen,
Ulli Rothweiler,
Richard Alan Engh,
Melissa R. Stasko,
Ilya Bederman,
Alberto C. S. Costa
et al.:
Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down Syndrome
Robin Lorenz,
Jian Wu,
Friedrich W. Herberg,
Susan Taylor,
Richard Alan Engh
:
Drugging the Undruggable: How Isoquinolines and PKA Initiated the Era of Designed Protein Kinase Inhibitor Therapeutics
Biochemistry 2021 DOI
Krzysztof Tarnowski,
Maria Klimecka,
Arkadiusz Ciesielski,
Grazyna Goch,
Anna Kulik,
Halina Fedak
et al.:
Two SnRK2-Interacting Calcium Sensor Isoforms Negatively Regulate SnRK2 Activity by Different Mechanisms
Kazi Asraful Alam,
Osman Gani,
Richard Alan Engh
:
Inhibitor binding of mutants of protein kinase A with GGGXXG and GXGXXA glycine-rich loop motifs
Journal of Molecular Recognition 2020 DOI
Balmukund Thakkar,
John Sigurd Mjøen Svendsen,
Richard Alan Engh
:
Density Functional Studies on Secondary Amides: Role of Steric Factors in Cis/Trans Isomerization
Anna Lucja Czarna,
Wang Jinhua,
Diana Zelencova,
Yao Liu,
Xianming Deng,
Hwan Geun Choi
et al.:
Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors
Balmukund Thakkar,
Richard Alan Engh
:
Comparative conformational analyses and molecular dynamics studies of glycylglycine methyl ester and glycylglycine N -methylamide
Balmukund Thakkar,
John Sigurd Mjøen Svendsen,
Richard Alan Engh
:
Cis/Trans Isomerization in Secondary Amides: Reaction Paths, Nitrogen Inversion and Relevance to Peptidic Systems
Balmukund Thakkar,
Marte Albrigtsen,
John Sigurd Mjøen Svendsen,
Jeanette hammer Andersen,
Richard Alan Engh
:
Biofocussed chemoprospecting: An efficient approach for drug discovery
Clemens Joachim Woywod,
Franz Gruber,
Richard Alan Engh,
Tor Flå
:
Dynamical models of mutated chronic myelogenous leukemia cells for a postimatinib treatment scenario: Response to dasatinib or nilotinib therapy
Dilip Narayanan,
Osman Gani,
Franz Gruber,
Richard Alan Engh
:
Data driven polypharmacological drug design for lung cancer: Analyses for targeting ALK, MET, and EGFR
Ulli Rothweiler,
Wenche Stensen,
Bjørn Olav Brandsdal,
Johan Isaksson,
Frederick Alan Leeson,
Richard Alan Engh
et al.:
Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules
Journal of Medicinal Chemistry 2016 DOI
Taavi Ivan,
Erki Enkvist,
Birgit Viira,
Ganesh babu Manoharan,
Gerda Raidaru,
Alexander Pflug
et al.:
Bifunctional ligands for inhibition of tight-binding protein-protein interactions
Bioconjugate chemistry 2016 DOI
Eric Martin,
Stefan Knapp,
Richard Alan Engh,
Henrik Moebitz,
Thibault Varin,
Benoit Roux
et al.:
Perspective on computational and structural aspects of kinase discovery from IPK2014
Biochimica et Biophysica Acta - Proteins and Proteomics 2015 DOI
Birgit S. Lauber,
Leo A. Hardegger,
Kazi Asraful Alam,
Bjarte Aarmo Lund,
Oliver Dumele,
Michael Harder
et al.:
Addressing the Glycine-Rich Loop of Protein Kinases by a Multi-Facetted Interaction Network: Inhibition of PKA and a PKB Mimic
Chemistry - A European Journal 18. Nov 2015 DOI
Osman A.B.S.M. Gani,
Balmukund Thakkar,
Dilip Narayanan,
Kazi Asraful Alam,
Peter Kyomuhendo,
Ulli Rothweiler
et al.:
Assessing protein kinase target similarity: Comparing sequence, structure, and cheminformatics approaches
Ulli Rothweiler,
Jonas Eriksson,
Wenche Stensen,
Frederick Alan Leeson,
Richard Alan Engh,
John Sigurd Svendsen
:
Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors
European Journal of Medicinal Chemistry 2015 DOI
Marina Alexeeva,
espen Åberg,
Richard Alan Engh,
Ulli Rothweiler
:
The structure of a dual-specificity tyrosine phosphorylation-regulated kinase 1A-PKC412 complex reveals disulfide-bridge formation with the anomalous catalytic loop HRD(HCD) cysteine.
Anna L Illert,
Anna K. Seitz,
Christoph Rummelt,
Stefanie Kreutmair,
Richard Alan Engh,
Samantha Goodstal
et al.:
Inhibition of aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and aurora kinases R763/ AS703569 and PHA-739358 in BCR-ABL transformed cells
Osman A.B.S.M. Gani,
Dilip Narayanan,
Richard Alan Engh
:
Evaluating the Predictivity of Virtual Screening for Abl Kinase Inhibitors to Hinder Drug Resistance
Kine Østnes Hanssen,
Jeanette hammer Andersen,
Trine Stiberg,
Richard Alan Engh,
Johan Svenson,
Anne-Marie Genevière
et al.:
Antitumoral and Mechanistic Studies of Ianthelline Isolated from the Arctic Sponge Stryphnus fortis
Anticancer Research 2012
espen Åberg,
Bjarte Aarmo Lund,
Alexander Pflug,
Osman A.B.S.M. Gani,
Ulli Rothweiler,
Taiana Maia De Oliveira
et al.:
Structural origins of AGC protein kinase inhibitor selectivities: PKA as a drug discovery tool
Biological chemistry 2012 DOI
Alexander Pflug,
Kenneth Johnson,
Richard Alan Engh
:
Anomalous dispersion analysis of inhibitor flexibility: a case study of the kinase inhibitor H-89
N. von Bubnoff,
S.P. Gorantla,
Richard Alan Engh,
Taiana Maia De Oliveira,
S. Thöne,
espen Åberg
et al.:
The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro
Oncogene 2011 DOI
Alexander Pflug,
Taiana Maia De Oliveira,
Dirk Bossemeyer,
Richard Alan Engh
:
Mutants of protein kinase A that mimic the ATP-binding site of Aurora kinase
Biochemical Journal 2011 DOI
ME Prime,
SM Courtney,
FA Brookfield,
RW Marston,
V Walker,
J Warne
et al.:
Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase
Journal of Medicinal Chemistry 2011 DOI
Rama Krishna Kancha,
Nikolas von Bubnoff,
Natalie Bartosch,
Christian Peschel,
Richard Alan Engh,
Justus Duyster
:
Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib
PLOS ONE 2011 DOI
Ulli Rothweiler,
espen Åberg,
Kenneth Johnson,
Tom Egil Hansen,
Jorunn B Jørgensen,
Richard Alan Engh
:
p38 alpha MAP Kinase Dimers with Swapped Activation Segments and a Novel Catalytic Loop Conformation
Journal of Molecular Biology (JMB) 2011 DOI
Taiana Maia De Oliveira,
Rafi Ahmad,
Richard Alan Engh
:
VX680 Binding in Aurora A: pi-pi Interactions Involving the Conserved Aromatic Amino Acid of the Flexible Glycine-Rich Loop
Journal of Physical Chemistry A 2011 DOI
Osman A.B.S.M. Gani,
Richard Alan Engh
:
Protein kinase inhibition of clinically important staurosporine analogues
Natural product reports (Print) 2010 DOI
Alexander Pflug,
Jevgenia Rogozina,
Darja Lavogina,
Erki Enkvist,
Asko Uri,
Richard Alan Engh
et al.:
Diversity of Bisubstrate Binding Modes of Adenosine Analogue-Oligoarginine Conjugates in Protein Kinase A and Implications for Protein Substrate Interactions
Journal of Molecular Biology (JMB) 2010 DOI
N von Bubnoff,
Richard Alan Engh,
espen Åberg,
J Sanger,
C Peschel,
J Duyster
:
FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro
Cancer Research 2009 DOI
Richard Alan Engh
:
Diversity of target profiles for ABL kinase inhibitors
2019
Richard Alan Engh
:
Protein structures "in crystallo" and "in vivo: do they match? Are they useful?
2018
Richard Alan Engh
:
Prospects for linking TKI protein kinase inhibition profiles to CML modelling parameters
2017
Balmukund Thakkar,
Osman Gani,
Richard Alan Engh
:
Practical Applications of Informatics Tools to Identify Drug Targets for Novel Compounds from Bio- and Chemoprospecting
2016
Richard Alan Engh
:
Unpredictable protein kinase flexibility: curse or blessing for inhibitor discovery?
2016
Marina Alexeeva,
espen Åberg,
Richard Alan Engh,
Ulli Rothweiler
:
The structure of a dual-specificity tyrosine phosphorylation-regulated kinase 1A-PKC412 complex reveals disulfide-bridge formation with the anomalous catalytic loop HRD(HCD) cysteine.
2016
Kazi Asraful Alam,
Ulli Rothweiler,
Richard Alan Engh
:
Static and dynamic interactions between the glycine-rich loop of protein kinases and ATP site inhibitors
2016
Marc Boomgaren,
Osman Gani,
Richard Alan Engh,
Jørn H Hansen
:
Bioactive Heterocycle Libraries for Anticancer Drug Discovery - Development of Covalent Binding TK Inhibitors
2016
Balmukund Thakkar,
Richard Alan Engh
:
PKA to Rho Kinase (ROCK): Assessing Structural Similarity via Surrogates
2015
Kazi Asraful Alam,
Richard Alan Engh
:
Selectivity Determinants of Aurora Kinases
2015
Kazi Asraful Alam,
Richard Alan Engh
:
The Glycine Rich Loop As Selectivity Determinant For Protein Kinase Inhibitors
2015
Marc Boomgaren,
Osman A.B.S.M. Gani,
Richard Alan Engh,
Jørn H Hansen
:
Bioactive Heterocycle Libraries for Anticancer Drug Discovery
2015
Balmukund Thakkar,
John Sigurd Mjøen Svendsen,
Richard Alan Engh
:
Design and Synthesis of diverse Piperazine-2,5-diones and their uncyclized analogues as potential kinase inhibitors
2013
espen Åberg,
Ole Morten Seternes,
Richard Alan Engh,
Franz Gruber
:
Fra Mutasjon til Medisin
2013
Balmukund Thakkar,
Jørn H Hansen,
Richard Alan Engh
:
Design and Synthesis of Tartaric Acid Bisamides: Focus on Kinase Inhibition
2013
Franz Gruber,
Thomas Ernst,
Kimmo Porkka,
Richard Alan Engh,
ingvild Mikkola,
Jacqueline Maier
et al.:
Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients
Leukemia 2012 DOI
RK Kancha,
N. von Bubnoff,
N Bartosch,
C. Peschel,
Richard Alan Engh,
J. Duyster
:
Irreversible inhibitors overcome lapatinib resistance due to ERBB2 kinase domain mutations
Onkologie (Basel) 2011
The 50 latest publications is shown on this page. See all publications in Cristin here →